Literature DB >> 11447164

Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.

M B Joshi1, A A Gam, R A Boykins, S Kumar, J Sacci, S L Hoffman, H L Nakhasi, R T Kenney.   

Abstract

Given the emerging difficulties with malaria drug resistance and vector control, as well as the persistent lack of an effective vaccine, new malaria vaccine development strategies are needed. We used a novel methodology to synthesize and fully characterize multiple antigen peptide (MAP) conjugates containing protective epitopes from Plasmodium falciparum and evaluated their immunogenicity in four different strains of mice. A di-epitope MAP (T3-T1) containing two T-cell epitopes of liver stage antigen-1 (LSA-1), a di-epitope MAP containing T-cell epitopes from LSA-1 and from merozoite surface protein-1, and a tri-epitope MAP (T3-CS-T1) containing T3-T1 and a potent B-cell epitope from the circumsporozoite protein central repeat region were tested in this study. Mice of all four strains produced peptide-specific antibodies; however, the magnitude of the humoral response indicated strong genetic restriction between the different strains of mice. Anti-MAP antibodies recognized stage-specific proteins on the malaria parasites in an immunofluorescence assay. In addition, serum from hybrid BALB/cJ x A/J CAF1 mice that had been immunized with the tri-epitope MAP T3-CS-T1 successfully inhibited the malaria sporozoite invasion of hepatoma cells in vitro. Spleen cells from immunized mice also showed a genetically restricted cellular immune response when stimulated with the immunogen in vitro. This study indicates that well-characterized MAPs combining solid-phase synthesis and conjugation chemistries are potent immunogens and that this approach can be utilized for the development of subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447164      PMCID: PMC98578          DOI: 10.1128/IAI.69.8.4884-4890.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.

Authors:  C A Moreno; R Rodriguez; G A Oliveira; V Ferreira; R S Nussenzweig; Z R Moya Castro; J M Calvo-Calle; E Nardin
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

Review 2.  The MAP system. A flexible and unambiguous vaccine design of branched peptides.

Authors:  B Nardelli; J P Tam
Journal:  Pharm Biotechnol       Date:  1995

3.  Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in BALB/c mice.

Authors:  M A Herrera; C de Plata; J M González; G Corradin; S Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  1994       Impact factor: 2.743

Review 4.  The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases.

Authors:  E H Nardin; G A Oliveira; J M Calvo-Calle; R S Nussenzweig
Journal:  Adv Immunol       Date:  1995       Impact factor: 3.543

5.  Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine.

Authors:  J H Tian; L H Miller; D C Kaslow; J Ahlers; M F Good; D W Alling; J A Berzofsky; S Kumar
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

6.  Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.

Authors:  R Wang; Y Charoenvit; G Corradin; R Porrozzi; R L Hunter; G Glenn; C R Alving; P Church; S L Hoffman
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

7.  Analysis of human T cell clones specific for conserved peptide sequences within malaria proteins. Paucity of clones responsive to intact parasites.

Authors:  I A Quakyi; J Currier; A Fell; D W Taylor; T Roberts; R A Houghten; R D England; J A Berzofsky; L H Miller; M F Good
Journal:  J Immunol       Date:  1994-09-01       Impact factor: 5.422

Review 8.  Malaria vaccine development.

Authors:  T R Jones; S L Hoffman
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

9.  Binding of malarial circumsporozoite protein to sulfatides [Gal(3-SO4)beta 1-Cer] and cholesterol-3-sulfate and its dependence on disulfide bond formation between cysteines in region II.

Authors:  C Cerami; F Kwakye-Berko; V Nussenzweig
Journal:  Mol Biochem Parasitol       Date:  1992-08       Impact factor: 1.759

10.  Immunization with a multiple antigen peptide containing defined B- and T-cell epitopes: production of bactericidal antibodies against group B Neisseria meningitidis.

Authors:  M Christodoulides; J E Heckels
Journal:  Microbiology       Date:  1994-11       Impact factor: 2.777

View more
  11 in total

1.  A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Authors:  Min Jin; Ying Yu; Huabing Qi; Yangli Xie; Nan Su; Xiaofeng Wang; Qiaoyan Tan; Fengtao Luo; Ying Zhu; Quan Wang; Xiaolan Du; Cory J Xian; Peng Liu; Haiyang Huang; Yue Shen; Chu-Xia Deng; Di Chen; Lin Chen
Journal:  Hum Mol Genet       Date:  2012-09-26       Impact factor: 6.150

2.  Multiple antigen peptide vaccines against Plasmodium falciparum malaria.

Authors:  Babita Mahajan; Jay A Berzofsky; Robert A Boykins; Victoria Majam; Hong Zheng; Rana Chattopadhyay; Patricia de la Vega; J Kathleen Moch; J David Haynes; Igor M Belyakov; Hira L Nakhasi; Sanjai Kumar
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

3.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

Review 4.  High throughput T epitope mapping and vaccine development.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Paolo Moretti; Fabrizio Manca
Journal:  J Biomed Biotechnol       Date:  2010-06-15

5.  Proteins of the Plasmodium falciparum two transmembrane Maurer's cleft protein family, PfMC-2TM, and the 130 kDa Maurer's cleft protein define different domains of the infected erythrocyte intramembranous network.

Authors:  Iryna Tsarukyanova; Judy A Drazba; Hisashi Fujioka; Satya P Yadav; Tobili Y Sam-Yellowe
Journal:  Parasitol Res       Date:  2009-01-07       Impact factor: 2.289

6.  Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.

Authors:  Luciana M Silva-Flannery; Monica Cabrera-Mora; Jianlin Jiang; Alberto Moreno
Journal:  Microbes Infect       Date:  2008-10-26       Impact factor: 2.700

7.  Promiscuous peptides on the nontypeable Haemophilus influenzae P6 outer membrane protein.

Authors:  Yuka Nomura; Yusuke Abe; Yoshiya Ishida; Hiroya Kobayashi; Yasuaki Harabuchi
Journal:  J Clin Immunol       Date:  2008-04-01       Impact factor: 8.317

8.  Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.

Authors:  Ivette Caro-Aguilar; Alexandra Rodríguez; J Mauricio Calvo-Calle; Fanny Guzmán; Patricia De la Vega; Manuel Elkin Patarroyo; Mary R Galinski; Alberto Moreno
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

9.  Exceptional hyperthyroidism and a role for both major histocompatibility class I and class II genes in a murine model of Graves' disease.

Authors:  Sandra M McLachlan; Holly A Aliesky; Chun-Rong Chen; Robert W Williams; Basil Rapoport
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

10.  DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice.

Authors:  Min Meng; Aihua Zhou; Gang Lu; Lin Wang; Guanghui Zhao; Yali Han; Huaiyu Zhou; Hua Cong; Qunli Zhao; Xing-Quan Zhu; Shenyi He
Journal:  BMC Infect Dis       Date:  2013-10-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.